Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Stone

Blood

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Blood|January 22, 2015
How I treat mixed-phenotype acute leukemiaOfir Wolach, Richard M Stone
Blood|September 11, 2004
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignanciesMartha Wadleigh, Daniel J DeAngelo, James D Griffin, et al.
Blood|June 7, 2019
Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignanciesMichael A Liu, Clark DuMontier, Anays Murillo, et al.
Blood|April 21, 2009
Identification of AML1-ETO modulators by chemical genomicsSteven M Corsello, Giovanni Roti, Kenneth N Ross, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
Blood|May 10, 2003
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationMartha Wadleigh, Paul G Richardson, David Zahrieh, et al.
Blood|October 2, 2004
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
Blood|June 27, 2009
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)Ivan M Borrello, Hyam I Levitsky, Wendy Stock, et al.
Blood|September 4, 2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone, Daniel J DeAngelo, Virginia Klimek, et al.
Blood|August 14, 2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Bayard L Powell, Barry Moser, Wendy Stock, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Blood|January 22, 2015
How I treat mixed-phenotype acute leukemiaOfir Wolach, Richard M Stone
Blood|September 11, 2004
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignanciesMartha Wadleigh, Daniel J DeAngelo, James D Griffin, et al.
Blood|June 7, 2019
Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignanciesMichael A Liu, Clark DuMontier, Anays Murillo, et al.
Blood|April 21, 2009
Identification of AML1-ETO modulators by chemical genomicsSteven M Corsello, Giovanni Roti, Kenneth N Ross, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
Blood|May 10, 2003
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationMartha Wadleigh, Paul G Richardson, David Zahrieh, et al.
Blood|October 2, 2004
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
Blood|June 27, 2009
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)Ivan M Borrello, Hyam I Levitsky, Wendy Stock, et al.
Blood|September 4, 2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone, Daniel J DeAngelo, Virginia Klimek, et al.
Blood|August 14, 2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Bayard L Powell, Barry Moser, Wendy Stock, et al.
Pageof 6